Cereno is planning to launch a new Phase 1 clinical trial to evaluate the pharmacological properties of CS014 in healthy volunteers.
Several new immunotherapeutic antibodies that inhibit checkpoint receptors on T cells to restimulate the immune system to target tumors have been approved to treat advanced stage lung cancer and ...
Safety and Efficacy of Osimertinib in Patients With Non–Small-Cell Lung Cancer and Uncommon Tumoral Epidermal Growth Factor Receptor Mutations: A Systematic Review and Single-Arm Meta-Analysis ...
GOTHENBURG, Sweden, Jan. 14, 2026 /PRNewswire/ -- Cereno Scientific (NASDAQ First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare ...
ROCKVILLE, Md., Sept. 11, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of ...
Homologous recombination-related (HRR) gene mutation profiling and the association with TMB in Chinese patients with urological cancer. This is an ASCO Meeting Abstract from the 2023 ASCO Annual ...
Epigenetics is the study of changes in organisms caused by modifying gene expression - by alcohol, for example - rather than alteration of the genetic code itself. Recent evidence suggests that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results